Emerging Biopharma and Rare Disease: The Top 5 Patient Engagement Solutions

Jun 08, 2017

Register Free: http://www.pharmexec.com/pe_w/emerging

As if patient identification and engagement weren't challenging enough, add in a rare disease study, and it can feel like a daunting process. Patient populations are small and widely dispersed around the globe, and finding the proper sites to support these patients is difficult. As an emerging biopharma company, limited resources can make these challenges that much harder.

In this webinar, Dr. Cynthia Jackson, Jessica Perry, and Nobu Kawasaki, experts in the study of rare diseases and patient recruitment at QuintilesIMS, will share their thoughts on how emerging biopharma companies can better impact enrollment and shorten the timelines of rare disease studies. Key themes of the discussion include:

  • Rare disease studies: Impact on patient recruitment strategies
  • Next-generation, data-driven approaches to support site ID and patient recruitment
  • Improving the patient experience during the course of a clinical trial


Dr. Cynthia Jackson, D.O., FAAP, Vice President and Head, Pediatric and Rare Disease Centers of Excellence, QuintilesIMS

Jessica Perry, Associate Director, Patient Recruitment Programs, QuintilesIMS

Nobu Kawasaki, Senior Manager, Analytical Center of Excellence, R&D Solutions, QuintilesIMS

Recorded date: June 8, 2017 / On Demand available until June 8, 2018.

Sponsor: QuintilesIMS

Register Free: http://www.pharmexec.com/pe_w/emerging

lorem ipsum